Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities
Presentation Slides Available on Celsion’s Website
“Ovarian cancer is typically diagnosed in its later stages and, as such, is very difficult to treat. The prognosis for patients with advanced ovarian cancer is poor, and treatment options are limited,” said Dr. Thaker. “As Principal Investigator for the Phase Ib dose-escalation OVATION 1 study evaluating patients newly diagnosed with Stage III/IV ovarian cancer and treated with four different doses of GEN-1, in combination with neoadjuvant chemotherapy (NAC), I was encouraged by this promising data.”
“Those data showed that of the 14 evaluable patients, 100% administered NAC plus the two higher doses of GEN-1 experienced an objective tumor response, defined as a partial or complete response. Only 60% of patients given the two lower doses had such a response. In addition, patients in the higher-dose cohorts had a high surgery success rate, with 88% achieving the optimal outcome of a complete resection. Pre- and post-treatment levels of key ovarian cancer biomarkers showed a marked reduction in immunosuppressive response across multiple biomarkers post-treatment, indicating GEN-1 may alter the tumor microenvironment and may improve ovarian cancer outcomes in combination with NAC. As Study Chair of the OVATION 2 study, I am eager to see if these results can be duplicated in a larger patient population,” Dr. Thaker added.
During the call, Dr. Thaker also spoke about the potential for other monotherapy and combination therapy approaches in development for ovarian cancer.
“We appreciate the attention Oppenheimer and Hartaj Singh have given the topic of ovarian cancer treatment,” said
Slide Presentation Available on Celsion’s Website
To view Dr. Thaker’s full slide presentation from the event, please visit Celsion’s corporate website at http://investor.celsion.com/scientific-presentations .
About GEN-1 Immunotherapy
GEN-1, designed using
The OVATION 2 Phase I/II study in patients newly diagnosed with Stage III/IV ovarian cancer, was initiated in the third quarter of 2018 and is designed with a single dose-escalation phase to 100 mg/m² of GEN-1 administered intraperitoneally in the Phase I portion, followed by a continuation at the selected dose in Phase II, in an open-label, 1:1 randomized design. The OVATION 2 Study will evaluate the effect of initial and maintenance dosing of GEN-1 on Progression Free Survival in up to 130 patients.
About Celsion Corporation
Forward-looking Statements
Forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant;
Celsion Investor Contact
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com
Or
LHA Investor Relations
212-838-3777
kgolodetz@lhai.com
# # #
Source: Celsion CORP